Shah, Chirayu <br/><br/>
Imaging biomarkers predict response to anti-HER2 (ErbB2) therapy in preclinical models of breast cancer.  [electronic resource] 

 -  Clinical cancer research : an official journal of the American Association for Cancer Research  Jul 2009 
 - 4712-21 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1557-3265 
<br/><br/><label>Standard No.: </label>10.1158/1078-0432.CCR-08-2635  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Antibodies, Monoclonal--pharmacology<br/>Antibodies, Monoclonal, Humanized<br/>Antineoplastic Agents--pharmacology<br/>Apoptosis--drug effects<br/>Breast Neoplasms--drug therapy<br/>Cell Line, Tumor<br/>Cell Proliferation--drug effects<br/>Diagnostic Imaging--methods<br/>Dideoxynucleosides<br/>Female<br/>Fluorine Radioisotopes<br/>Fluorodeoxyglucose F18<br/>Glucose--metabolism<br/>Humans<br/>Mammary Neoplasms, Experimental--drug therapy<br/>Mice<br/>Mice, Nude<br/>Mice, Transgenic<br/>Positron-Emission Tomography<br/>Prognosis<br/>Receptor, ErbB-2--antagonists & inhibitors<br/>Reproducibility of Results<br/>Trastuzumab<br/>Xenograft Model Antitumor Assays